Some ways to bring in more income are difficult or extensive, but a few small overlooked tactics can create a significant bottom-line increase. Medscape Business of Medicine
Category: News
Visual Benefits Of Anti-VEGF Therapy May Diminish Upon Extended Dosing
Long-term outcomes of anti-VEGF therapy for neovascular age-related macular degeneration suggest that eyes with good visual acuities require long-term regular dosing, according to a presentation here.
Visual Benefits Of Anti-VEGF Therapy May Diminish Upon Extended Dosing
Long-term outcomes of anti-VEGF therapy for neovascular age-related macular degeneration suggest that eyes with good visual acuities require long-term regular dosing, according to a presentation here.
KalVista raises £8 million in series A round of funding
KalVista Pharmaceuticals, a new ophthalmology company with a focus on diabetic macular edema (DME), has raised £8 million in a series A round from leading life sciences investors Novo A/S and SV Life Sciences.
Kellogg Researcher Helping Eye Care Providers Better Assess Driving In Older Adults
Drivers over age 65 are the fastest-growing segment of the driving population, and their eye care providers ophthalmologists and optometrists are playing an increasingly important role in assessing their ability to drive safely. Kellogg researcher Davi…
KalVista Pharmaceuticals Launched With 8 Million In Series A Funding To Develop Novel Class Of Drugs For Diabetic Macular Edema
KalVista Pharmaceuticals (“KalVista”), a new ophthalmology company with a focus on diabetic macular edema (DME), has raised GBP8 million in a series A round from leading life sciences investors Novo A/S and SV Life Sciences.
KalVista Pharmaceuticals Launched With 8 Million In Series A Funding To Develop Novel Class Of Drugs For Diabetic Macular Edema
KalVista Pharmaceuticals (“KalVista”), a new ophthalmology company with a focus on diabetic macular edema (DME), has raised GBP8 million in a series A round from leading life sciences investors Novo A/S and SV Life Sciences.
KalVista Pharmaceuticals Launched With 8 Million In Series A Funding To Develop Novel Class Of Drugs For Diabetic Macular Edema
KalVista Pharmaceuticals (“KalVista”), a new ophthalmology company with a focus on diabetic macular edema (DME), has raised GBP8 million in a series A round from leading life sciences investors Novo A/S and SV Life Sciences.
MIVI-TRUST Outcomes Strengthen Support Of Ocriplasmin For Vitreomacular Adhesion
Ocriplasmin may become the first pharmacologic option for patients with vitreomacular adhesion, according to two presentations here.
Kellogg Researcher Helping Eye Care Providers Better Assess Driving In Older Adults
Drivers over age 65 are the fastest-growing segment of the driving population, and their eye care providers-ophthalmologists and optometrists-are playing an increasingly important role in assessing their ability to drive safely.
Landmark 8 Millionth U.S. Patent Awarded to Second Sight Medical’s Retinal Prosthesis
On July 31, 1790, the first United States patent was issued to Samuel Hopkins for a process for making potash. Millions of patents have been issued in the 221 years since, many of them related to medical devices and technologies. This week, the United States Patent and Trademark Office (USPTO) announced the awarding of the 8 millionth patent – (Read more...)
Abbott Receives CE Mark For Healon EndoCoat Protective Gel For Cataract Surgery
Abbott announced today that it has expanded its Healon® family of ophthalmic viscosurgical devices (OVDs) with the European CE Mark of Healon EndoCoat OVD.
Sosei To Receive Grant From NEDO’s FY2011 Innovation Promotion Programme For Development Of Innovative Ophthalmic Solutions
Sosei Group Corporation, announces that its wholly owned subsidiary Activus Pharma Co., Ltd. (“Activus”) is to receive a grant for its “Development of Innovative Ophthalmic Solutions” from the New Energy and Industrial Technology Development Organizati…
Volk Pictor Portable Imager At Vision West
Mentor, Ohio (August 19, 2011) – Volk Optical’s new Pictor digital imaging device will demonstrate its ease of use outside the office at Vision West September 22 – 24, 2011 at the Sands Expo and Convention Center (Las Vegas, Nev.). At Volk’s exhibit in…
ThromboGenics Announces New Phase III Ocriplasmin Data Presented At The 2011 Annual Meeting Of The American Society Of Retina Specialists (ASRS)
New data presented by leading retinal specialists Dr Pravin U. Dugel, MD (Phoenix, AZ) and Dr Peter K. Kaiser, MD (Cleveland, OH)
Time-release corticosteroid implant effective in treating uveitis
A team of researchers comparing the two leading treatment approaches for the eye condition uveitis, which is the fifth leading cause of blindness in the US, have found that a time-release corticosteroid implant placed surgically in the eye is similarly…
Short-Term Dark Adaptation May Be More Reliable In Identifying Primary Angle-Closure Suspects
Assessment of the anterior chamber angle configuration may be more reliable if performed after a short-term dark adaptation of 3 minutes, a study found.
Vision Problems Common After Glaucoma Surgery
More than half of people getting a certain type of glaucoma surgery may suffer from temporary, sometimes severe vision loss afterwards, suggests a new study. A smaller proportion — about 8 in every 100 — could have some degree of permanent vision los…
Vision Problems Common After Glaucoma Surgery
More than half of people getting a certain type of glaucoma surgery may suffer from temporary, sometimes severe vision loss afterwards, suggests a new study. A smaller proportion — about 8 in every 100 — could have some degree of permanent vision los…
Short-Term Dark Adaptation May Be More Reliable In Identifying Primary Angle-Closure Suspects
Assessment of the anterior chamber angle configuration may be more reliable if performed after a short-term dark adaptation of 3 minutes, a study found.